Taking a GLP-1 before surgery, endoscopy or any procedure with anesthesia or deep sedation matters because these medications slow how fast your stomach empties. The advice has shifted. An earlier anesthesiology approach suggested considering a hold. Multisociety guidance from 2024 moved to shared decision-making and says therapy may be continued in patients without elevated risk. You and your surgical, anesthesia and prescribing teams decide together. This article gives no hold schedule, on purpose.
Key takeaways
- GLP-1 medications slow stomach emptying, and since November 2024 FDA labeling has warned that food left in the stomach can be inhaled into the lungs under general anesthesia or deep sedation (Wegovy label, FDA, 2025).
- An earlier American Society of Anesthesiologists approach suggested considering a hold, while October 2024 multisociety guidance moved to shared decision-making and says therapy may be continued in patients without elevated risk (Clinical Gastroenterology and Hepatology, 2025).
- The FDA label does not tell you to stop your medication or change your fasting; it says the data are insufficient and asks you to tell your providers before any planned procedure.
- The same concern applies to compounded semaglutide and tirzepatide, so tell your team the product is compounded.
- Your surgical, anesthesia and prescribing teams make this decision with you, and you should not stop or change your medication on your own.
Why taking a GLP-1 before surgery matters
GLP-1 medications slow how quickly the stomach empties, and anesthesia is safest on an empty stomach. If food is still there when the body's protective reflexes are dulled, it can move into the lungs.
Fasting rules exist because general anesthesia and deep sedation blunt the reflexes that normally guard your airway. Pulmonary aspiration means stomach contents getting into the lungs. GLP-1 receptor agonists are drugs that mimic glucagon-like peptide-1, a gut hormone, and the Wegovy label states plainly that the drug delays gastric emptying. The label also describes rare postmarketing reports of aspiration in people taking GLP-1s who had elective procedures under general anesthesia or deep sedation and still had stomach contents despite reporting that they had fasted (Wegovy label, FDA, 2025). Postmarketing reports are collected after a drug is on the market. They signal a possible problem but cannot show how often it happens.
Some of the clearest quantitative data come from a 2024 systematic review and meta-analysis by Hiramoto and colleagues that pooled 15 studies (Am J Gastroenterol, 2024). In five scintigraphy studies (247 participants), the gastric emptying half-time was 138.4 minutes on a GLP-1 versus 95.0 minutes on placebo, a pooled difference of about 36 minutes. Scintigraphy is an imaging test that tracks a meal containing a small radioactive tracer. Half-time is how long it takes half the stomach's contents to leave. In ten acetaminophen absorption studies (411 participants), a method that mainly reflects liquid emptying, there was no significant delay. The authors judged the delay to be limited in size compared with standard pre-procedure fasting periods.
These findings have limits. The meta-analysis measured gastric emptying, not aspiration events. It could not reach firm conclusions about aspiration because clinical data were lacking (Am J Gastroenterol, 2024). The 2024 guidance itself acknowledges that data are too limited to build fully evidence-based guidelines (Clinical Gastroenterology and Hepatology, 2025). For stomach side effects in day-to-day use, see our guide to GLP-1 side effects week by week. This article covers procedures only.
What did the earlier ASA approach say?
Before the 2024 multisociety guidance, the American Society of Anesthesiologists (ASA) had suggested that clinicians consider holding GLP-1s before procedures. A suggestion to consider a hold is not a requirement to stop.
This article does not restate the details or timing of that earlier approach, and it gives no hold schedule.
The earlier approach has not disappeared. A Guideline Central summary of the 2024 guidance notes that if a hold is chosen, the right length is unknown, and it suggests deferring to the original ASA approach (Clinical Gastroenterology and Hepatology, 2025). Whether any hold applies to you is a decision for your surgical, anesthesia and prescribing teams, made with you.
What changed in the October 2024 multisociety guidance?
The October 2024 guidance replaced a single rule for everyone with shared decision-making. It says GLP-1 therapy may be continued before surgery in patients without elevated risk of delayed gastric emptying and aspiration.
The guidance was published online on October 29, 2024 (Clinical Gastroenterology and Hepatology, 2025). It was issued as unified guidance from multiple professional societies. It covers GLP-1 use regardless of why the drug is prescribed, including type 2 diabetes, overweight and obesity, and heart failure. Its key points:
- Decisions are shared between you and your procedural, anesthesia and prescribing teams, weighing your metabolic need for the drug against your individual risk.
- The escalation phase, the period when the dose is still being stepped up, is linked to a higher risk of delayed emptying than the maintenance phase.
- Risk should be assessed early enough to allow diet changes and, if stopping is indicated, planning for how to manage your condition in the meantime (called bridging).
- Practices are encouraged to build multidisciplinary protocols.
Active stomach symptoms and other conditions that slow digestion are worth raising with your team, because they can shape how your risk is judged. For higher-risk patients, the guidance stresses assessing risk early enough to allow diet changes before the procedure, and the AGA endoscopy update discusses ultrasound for people whose symptoms suggest retained stomach contents (AGA, Clin Gastroenterol Hepatol, 2024). Holding the medication remains an option. Any hold is decided with your care team.
Stopping has trade-offs too. The guidance asks teams to weigh metabolic need against individual risk; for someone with diabetes, for example, a pause can affect blood sugar control. There is also an honest tension in the evidence. The guidance links the escalation phase to higher risk of delayed emptying than the maintenance phase. Yet the Hiramoto meta-regression, a statistical check of whether study features changed the results, found that treatment duration did not change measured gastric emptying (Am J Gastroenterol, 2024). Both points come from limited data, which is one more reason the decision is individual.
Why do summaries of the guidance contradict each other?
Summaries contradict each other because several documents from different bodies appeared in quick succession, and pages often blend them or quote an older one as current.
| Document | When | Core stance | Scope |
|---|---|---|---|
| Earlier ASA approach | Before Oct 2024 | Consider holding; still referenced if a hold is chosen | Not detailed in our verified sources |
| AGA endoscopy update | Nov 2023 | Individualized; no data to support stopping for everyone | Elective endoscopy |
| Multisociety guidance | Oct 2024 | Shared decisions; may continue if not at elevated risk; hold stays an option | Time around surgery or procedures, any indication |
| FDA label warning | Nov 2024 | Data insufficient to recommend fasting changes or stopping; tell providers | Labeled product (Wegovy) |
The FDA piece is often misreported. The label says available data are insufficient to recommend ways to reduce aspiration risk, including whether changing fasting instructions or temporarily stopping the drug reduces retained stomach contents. What it does say is that patients should inform their healthcare providers before any planned surgery or procedure (Wegovy label, FDA, 2025). The 2024 multisociety guidance applies to GLP-1 receptor agonists as a class, so ask your team about the specific product you use.
Some pages still present a hold as the standard and hand readers a schedule. Others overstate the 2024 update in one direction or the other, when it says therapy may be continued in patients without elevated risk of delayed emptying and aspiration. Our reading: the guidance allows continuing for patients without elevated risk, and any hold is a case-by-case decision made with your care team. Guidance keeps evolving, and your hospital or surgery center may have its own protocol, so follow your care team's instructions for your procedure.
GLP-1 before endoscopy or colonoscopy
For endoscopy, the AGA favored an individualized approach over stopping GLP-1s for everyone. Its November 2023 Rapid Clinical Practice Update said there were no data to support all patients stopping before elective endoscopy (AGA, Clin Gastroenterol Hepatol, 2024).
The update, by Hashash, Thompson and Wang, was peer reviewed. It noted that facilities were struggling to revise their pre-procedure protocols despite a lack of high-level evidence. A Guideline Central summary notes that transabdominal ultrasonography, a scan through the skin of the abdomen, is discussed for people whose symptoms suggest retained stomach contents (AGA, Clin Gastroenterol Hepatol, 2024).
Because GLP-1s slow stomach emptying, endoscopy units may adjust fasting or preparation instructions for people who take them. The 2024 multisociety guidance on the perioperative period, meaning the time around a procedure, is also relevant. Bowel-prep and diet instructions come from your endoscopy unit, so tell them about your GLP-1 when you book.
What to tell your surgeon, anesthesiologist and endoscopist
Tell every team involved that you take a GLP-1, and do it at booking or pre-op screening, not on the morning of the procedure. Early notice gives them time to assess your risk and adjust the plan.
Share these details:
- The drug name and active ingredient (semaglutide or tirzepatide).
- Whether it is a brand product or compounded.
- How often you take it and the date of your last dose.
- Whether you are still in the escalation phase or recently changed strength.
- Any current nausea, vomiting, constipation, bloating or abdominal pain.
- Whether you have diabetes or another condition that slows digestion.
- Your other medications and supplements.
- Contact details for your prescribing clinician.
Tell your prescribing clinician about the procedure too, so the teams can coordinate. Do not stop or change your medication on your own. If you need emergency surgery or care, do not delay it. Tell the emergency team about your GLP-1 if you can.
Compounded semaglutide and tirzepatide: does the guidance apply?
Yes. The gastric-emptying concern comes from how the drug class works, so it applies to compounded products as well as brands.
Compounded semaglutide has the same active ingredient as Ozempic and Wegovy, and compounded tirzepatide has the same active ingredient as Mounjaro and Zepbound. Those brands are FDA-approved. Compounded medications are not FDA-approved, and they are not equivalent to or generic versions of the brands. They are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Brand labels describe the brand products, but the shared mechanism, and the 2024 guidance's class-wide scope, are the reasons to disclose a compounded GLP-1 just as you would Ozempic before surgery and anesthesia. Tell your team the product is compounded and bring the pharmacy label. For more on how the two differ, see branded vs compounded GLP-1.
How access works through New Blue
New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.
- You complete a structured asynchronous intake for the Semaglutide GLP-1 pathway. Some treatments or states may require a live visit.
- A licensed clinician reviews your intake and decides whether treatment is appropriate. Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.
- If prescribed, a licensed partner pharmacy ships the injectable medication directly to you.
People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, should not use these medications. A licensed clinician screens for this during review. See semaglutide pancreatitis risk and the semaglutide evidence summary.
The Semaglutide and Tirzepatide GLP-1 pathways have delivery limits in some states. Availability varies by state; check state availability. If you have a procedure planned, tell the licensed clinician reviewing your care as well as your surgical team. For current pricing, see the Semaglutide GLP-1 pathway. New Blue is LegitScript certified, serves adults 21 and older, and is not for emergencies.
Frequently Asked Questions
Do I have to stop my GLP-1 a week before surgery?
Not necessarily. An earlier ASA approach suggested considering a hold rather than requiring one. The 2024 multisociety guidance makes the decision individual and says therapy may be continued in patients without elevated risk. If a hold is chosen, the right length is unknown, and your surgical, anesthesia and prescribing teams decide with you.
Can I keep taking semaglutide before a colonoscopy?
It depends on your situation and your endoscopy unit. The AGA favors an individualized approach and found no data to support stopping for everyone before elective endoscopy. Tell the unit about your medication when you book and follow their preparation instructions.
Does the FDA say to stop GLP-1s before surgery?
No. The FDA label says available data are insufficient to recommend stopping the drug or changing fasting to reduce aspiration risk. It tells patients to inform their healthcare providers before any planned surgery or procedure.
Is the risk higher if I just started a GLP-1?
The 2024 guidance links the escalation phase, when the dose is still being increased, to higher risk of delayed gastric emptying. One meta-analysis found treatment duration did not change measured emptying, so the evidence is mixed. Tell your team where you are in treatment.
What if I forgot to tell my surgical team about my GLP-1?
Call the surgical or pre-op team as soon as possible. Early notice gives them time to assess your risk and adjust the plan if needed. Do not stop or change your medication on your own while you wait.
Does this guidance apply to tirzepatide?
Yes. Tirzepatide acts on the GLP-1 receptor as well as the GIP receptor (a receptor for another gut hormone), so the same gastric-emptying concern is relevant. The 2024 guidance covers GLP-1 receptor agonists as a class regardless of why they are prescribed. Tell your team if your tirzepatide is compounded.
Sources
- Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clinical Gastroenterology and Hepatology, 2025 (published online October 2024). https://doi.org/10.1016/j.cgh.2024.10.003
- Hashash JG, Thompson CC, Wang AY. AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication. Clinical Gastroenterology and Hepatology, 2024. https://pubmed.ncbi.nlm.nih.gov/37944573/
- WEGOVY (semaglutide) injection, for subcutaneous use: Prescribing Information. U.S. Food and Drug Administration (Drugs@FDA), 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
- Hiramoto B, et al. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management. The American Journal of Gastroenterology, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11150091/
Medical disclaimer: This article is for education only and is not medical advice. Decisions about your medication before any surgery or procedure belong to your surgical, anesthesia and prescribing teams, and treatment decisions are made by a licensed clinician. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.